NL-OMON52125尚未招募2 期
Treatment of limited Oligo Metastatic disease in Esophageal and Stomach carcinoma; TOMES trial - Treatment of limited Metastatic disease in Esophageal and Stomach carcinoma
Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 73 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 73
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •histologically proven cT2-4aN0-2 adenocarcinoma carcinoma of the oesophagus,
- •gastroesophageal junction or stomach.
- •histologically proven metastases from esophageal or gastric cancer or if
- •histologic biopsy is not possible, radiological images are highly suspicious
- •for metastases
- •Maximum of 3 metastases in one organ OR M1 lymph node metastasis restricted
- •to one region (brain metastases are allowed)
- •Resectable primary tumor.
- •Metastases eligible for adequate local treatment.
- •good performance status (WHO performance status 0-2) (appendix I).
- •ASA 1-2 (appendix II).
- •written informed consent.
- •age >= 18
- •fit to receive palliative systemic treatment
排除标准
- •pregnancy, lactating female
- •peritoneal metastases or positive cytology from abdominal washings.
- •patients participating in other trials that would interfere with the
- •implementation of this protocol.
- •Patients with N3M1 disease
- •Unable or unwilling to undergo systemic palliative treatment
研究者
相似试验
进行中（未招募）
1 期
Metastasis-directed therapy, whether or not in combination with hormone therapy, in patients with prostate cancer recurrence after initial treatment and a maximum of 5 metastasen.EUCTR2022-000066-18-BEniversitaire Ziekenhuizen Leuven873
招募中
1 期
Metastasis-directed therapy, whether or not in combination with hormone therapy, in patients with prostate cancer recurrence after initial treatment and a maximum of 5 metastases.Oligorecurrent hormone-sensitive prostate cancer patientsCTIS2022-502373-42-00Z Leuven873
招募中
1 期
Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressive lesions.CTIS2022-502254-13-00Z Leuven246
招募中
1 期
Intensified treatment in patients with oligometastatic pancreatic cancer - multimodal surgical treatment versus systemic chemotherapy alone: a randomized controlled trial - METAPANColigometastatic pancreatic cancerCTIS2023-503558-10-00niversitaetsmedizin Goettingen425
进行中（未招募）
不适用
Treatment of locally advanced or metastatic non-small cell lung cancer with Pemetrexed (Alimta) and Gemcitabine or Gemcitabine and Carboplatin: The PAGe study. - The PAGe studyEUCTR2005-001577-97-SEGunnar Hillerdal96